VivoSeq
Other

Blood Transfusion

18

Pipeline Programs↗

6

Active Trials↗

11

Companies Involved↗

Blood Transfusion is an emerging landscape with 18 programs across 11 companies. The most active players are Mononuclear Therapeutics Ltd., Pascoe Pharmazeutische Praeparate GmbH, Pierre Fabre Pharma GmbH. 2 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

73/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Mononuclear Therapeutics Ltd.

1 program

Phase 1P

Pascoe Pharmazeutische Praeparate GmbH

1 program

Phase 1P

Pierre Fabre Pharma GmbH

1 program

Phase 1Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3Novartis logo

Novartis

2 programs

Phase 3A

Amring

1 program

Approved

Pipeline

Programs by Phase

Preclinical4

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Furosemide

Validus Pharmaceuticals

Epsilon-Aminocaproic Acid (EACA)

National Heart, Lung, and Blood Institute (NHLBI)

HBOC-201

Johns Hopkins University

Phase 15

Donor Blood

Vanderbilt University Medical Center

Banked Blood

Vanderbilt University Medical Center

Iron Sulphate

Pierre Fabre Pharma GmbH

Red Blood Cell

University of Pittsburgh

N-Acetylcystine

University of California, San Francisco

Phase 23

Deferasirox

Novartis

ASD CB-MNC Injection.

State-Financed Health Facility "Samara Regional Medical Center Dinasty"

Umbilical Cord Blood Unit

Weill Medical College of Cornell University

Phase 34

Deferoxamine

Alnylam Pharmaceuticals

ICL670

Novartis

ALD-101

Aldagen

Low-Titer O-Group Whole Blood

Xijing Hospital

Approved2

Tranexamic Acid

Amring

Ferinject

Vifor Pharma

Analysis

Trial Status

39

clinical trials

Completed19 · 49%
Unknown status6 · 15%
Withdrawn4 · 10%
Recruiting3 · 8%
Terminated3 · 8%
Not yet recruiting3 · 8%
Other1 · 3%

Clinical Trials

Trial Activity

39 trials

Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes
Recruiting·—·Phase 4·NCT06840756·11,082 enrolled
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
Recruiting·RRush University Medical Center·Phase 1·NCT03849443·604 enrolled
S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion
Recruiting·—·Phase 1·NCT03999229·35 enrolled
Pilot Study of Whole Blood Transfusion for Trauma Brain Injury (TBI)
Not yet recruiting·OOregon Health and Science University·Phase 3·NCT06184828·100 enrolled
Optimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock
Not yet recruiting·XXijing Hospital·Phase 3·NCT07129031·180 enrolled
Personalized (Demand-Informed) Blood Transfusion Protocol for Cardiac Patients
Not yet recruiting·—·Preclinical·NCT07671469·900 enrolled
A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 4·NCT00216541·110 enrolled
Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy
Completed·HHospital for Special Surgery, New York·N/A·NCT02253810·89 enrolled
Study the Effect of Blood Transfusion on Oxidant-antioxidant Status in Term and Near-term Neonates
Completed·—·Phase 1·NCT03767361·65 enrolled
Postoperative Blood Transfusion for Frail Elderly With Hip Fracture
Completed·UUniversity of Aarhus·Phase 1·NCT01102010·284 enrolled
A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270036·1 enrolled
Detection of Autologous DEHP (DiEthylHexyl Phthalate)-Free Blood Transfusion in Anti-doping
Completed·—·N/A·NCT02423135·20 enrolled
Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?
Completed·MMayo Clinic·Phase 4·NCT01714336·138 enrolled
The Effect of Blood Transfusion on Venoarterial PCO2 Difference in Cardiac Surgery
Completed·TTurkiye Yuksek Ihtisas Education and Research Hospital·N/A·NCT03245502·127 enrolled
Autologous Blood Transfusion After Local Infiltration
Completed·NNorthern Orthopaedic Division, Denmark·N/A·NCT01576263·52 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)